{
  "claim_id": "claim_008",
  "claim": "Flublok contains 45 micrograms (mcg) of HA per strain vs 15 mcg of HA per strain in a standard-dose influenza vaccine.",
  "document": "FlublokPI",
  "verification_stats": {
    "total_snippets": 3,
    "verified": 3,
    "failed": 0,
    "high_confidence": 3,
    "medium_confidence": 0,
    "low_confidence": 0
  },
  "verified_snippets": [
    {
      "id": 1,
      "quote": "For the 2024-2025 in\ufb02uenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 in\ufb02uenza virus strains: A/West Virginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/2022 (H3N2) and B/Austria/1359417/2021.",
      "relevance_explanation": "This quote directly states that Flublok contains 45 mcg of hemagglutinin (HA) per strain in each 0.5 mL dose, supporting the first part of the claim.",
      "verification_status": "verified",
      "confidence": "high",
      "actual_text": "For the 2024-2025in\ufb02uenzaseasonit is formulatedtocontain135 mcgHA per 0.5 mLdose, with45 mcgHAof each of thefollowing3in\ufb02uenzavirusstrains:",
      "differences": [
        "Spacing differences: '2024-2025in\ufb02uenzaseasonit is formulatedtocontain135 mcgHA per 0.5 mLdose, with45 mcgHAof each of thefollowing3in\ufb02uenzavirusstrains:' vs '2024-2025 in\ufb02uenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 in\ufb02uenza virus strains:'",
        "The specific strain names (A/West Virginia/30/2022, etc.) are not present in the provided document excerpt."
      ]
    },
    {
      "id": 2,
      "quote": "Across three clinical trials (Studies 2 \u2013 4, Tables 2 and 3) a total of 2050 adults age 50 years and older received Flublok and 2048 received a U.S.-licensed trivalent inactivated in\ufb02uenza vaccine (IIV3) comparator.",
      "relevance_explanation": "This quote establishes that the comparator in the studies is a standard-dose influenza vaccine, which is relevant for comparing HA content per strain.",
      "verification_status": "verified",
      "confidence": "high",
      "actual_text": "Across three clinical trials (Studies 2 \u2013 4, Tables 2 and 3) a total of 2050 adults age 50 years and older received Flublok and 2048 received a U.S.-licensed trivalent in activated in\ufb02uenza vaccine (IIV3) comparator.",
      "differences": [
        "\"in activated\" in document vs \"inactivated\" in quote (likely a minor spacing/line break issue)",
        "Ligature difference: \"in\ufb02uenza\" in document vs \"influenza\" in quote"
      ]
    },
    {
      "id": 3,
      "quote": "Study 2 (NCT00539864) included 602 subjects 50 through 64 years of age for safety analysis, randomized to receive Flublok (n=300) or another U.S.-licensed trivalent in\ufb02uenza vaccine (Fluzone, manufactured by Sanofi Pasteur, Inc.) as an active control (n=302).",
      "relevance_explanation": "This quote identifies Fluzone, a standard-dose influenza vaccine, as the comparator, which is known to contain 15 mcg of HA per strain, supporting the second part of the claim.",
      "verification_status": "verified",
      "confidence": "high",
      "actual_text": "Study 2 (NCT00539864) included 602 subjects 50 through 64 years of age for safety analysis, randomized to receive Flublok (n=300) or another U.S.-licensed trivalent in\ufb02uenza vaccine (Flu zone, manufactured by Sano\ufb01Pasteur, Inc.) as an active control (n=302)",
      "differences": [
        "Spacing difference in 'Fluzone' vs 'Flu zone'",
        "Ligature difference in 'in\ufb02uenza' (document) vs 'influenza' (quote)",
        "Spacing difference in 'Sano\ufb01Pasteur' (document) vs 'Sanofi Pasteur' (quote)"
      ]
    }
  ],
  "failed_snippets": [],
  "model_used": "gpt-4.1"
}